Investor Presentation for the quarter and half year ended September 30, 2026

Ref: MHL/Sec&Legal/2026-27/57 November 03, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation for the quarter and half year ended September 30, 2026. A copy of the said presentation is also being uploaded on the Company’s website at www.metropolisindia.com. You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head - Legal & Secretarial Encl.: a/a Q2 & H1FY27 Investor Presentation Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been Certain matters discussed in this Presentation may contain statements regarding the prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely Company’s market opportunity and business prospects that are individually and for information purposes and do not constitute any offer, recommendation or invitation to collectively forward-looking statements. Such forward-looking statements are not purchase or subscribe for any securities, and shall not form the basis or be relied on in guarantees of future performance and are subject to known and unknown risks, connection with any contract or binding commitment whatsoever. No offering of securities uncertainties and assumptions that are difficult to predict. These risks and uncertainties of the Company will be made except by means of a statutory offering document containing include, but are not limited to, the performance of the Indian economy and of the detailed information about the Company. economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company’s ability to successfully implement its This Presentation has been prepared by the Company based on information and data strategy, the Company’s future levels of growth and expansion, technological which the Company considers reliable, but the Company makes no representation or implementation, changes and advancements, changes in revenue, income or cash flows, warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, the Company’s market preferences and its exposure to market risks, as well as other accuracy, completeness, fairness and reasonableness of the contents of this risks. The Company’s actual results, levels of activity, performance or achievements could Presentation. This Presentation may not be all inclusive and may not contain all of the differ materially and adversely from results expressed in or implied by this Presentation. information that you may consider material. Any liability in respect of the contents of, or The Company assumes no obligation to update any forward-looking information contained any omission from, this Presentation is expressly excluded. in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. H1 F Y 2 7 Delivery Ahead Of Guidance REVENUE EBITDA PAT INR 947 Cr INR 248 Cr INR 132 Cr 16% YoY 25% YoY 35% YoY EBITDA MARGIN PAT MARGIN 26.2% 14.0% 190 bps 200 bps Sustained demand momentum and increasing H1FY27 EBITDA grew by 190 bps driven by, Mid-teen revenue growth delivered despite no throughput from the expanded Lab & Center operating leverage, automation. Productivity price hikes, demonstrating strong underlying network enabled the company to outperform its gains and continued process efficiencies. demand and volume-led growth. growth guidance Q2 F Y 2 7 Consistent Delivery Over Last 4 Quarters REVENUE EBITDA PAT INR 497 Cr INR 135 Cr INR 75 Cr 16% YoY 24% YoY 43% YoY EBITDA MARGIN PAT MARGIN 27.2% 15.2% 180 bps 290 bps Growth driven by volume and favourable mix, Q2FY27 EBITDA grew by 180 bps driven by Growth in patient and test volumes, with broad-based performance across channels, operating leverage, automation, and continued complemented by a richer test mix and improved regions and TruHealth & Specialty Diagnostics. process efficiencies. realizations Q2 F Y 2 7 Key Performance Indicators: Strong broad-based performance Share of revenue by segment, Q2FY27 B2C REVENUE B2B REVENUE INR 289 Cr INR 208 Cr Specialty INR 198 Cr) 17% YoY 15% YoY TruHealth INR 86 Cr) ▲ ▲ 40% 25% Semi-specialty Routine PATIENT VOLUME TEST VOLUME 4.07 Mn 8.68 Mn Revenue growth by segment, Q2FY27 YoY 10% YoY 11% YoY Specialty 20% TruHealth 20% REVENUE PER PATIENT REVENUE PER TEST INR 1,221 INR 572 Semi-specialty 16% ▲ 6% YoY No price increase ▲ 5% YoY Routine 4% Q2 F Y 2 7 · CHAN N EL MI X B2C revenue up 17% YoY & B2B revenue up 15% YoY B2C · 58% B2B · 42% B2C B2B 17% YoY 15% YoY Owned and Franchise centers (urban and rural) B2B labs, hospitals, government, corporate & clinical trials TruHealth Growth Specialty Growth TruHealth Growth Specialty Growth 21% 23% 19% 18% • Home collection in 60 minutes, • Dedicated helpdesk for high-end faster reports in key markets. partners. • Local digital push and app • Stronger specialty portfolio adoption lifting outlet volumes. focused on genomics. • MetLink programme and Partner • Wider Partner Portal use improves MetLink – Flagship Franchisee Partner B2B Partner training and Engagement Portal deepening franchisee ties. Engagement Programme transparency. Q2 F Y 2 7 · R E VE N UE GR OWT H TruHealth & Specialty : Strategic Growth Engines Outperforming TruHealth Specialty Strong revenue momentum, premium mix & digital acceleration GROWTH CONTRIBUTION GROWTH CONTRIBUTION 20% 17% 20% 40% Volume growth led by Tier 3 and rural markets. Diet and dietician bundles gained B2C traction, 30% via digital. Bundling lifted RPT on premium packs. Wellness Zone at Key Centres for Series of Genomics Symposiums RPP rising in focus cities on across the country for Specialist Consultative TruHealth Connect Truhealth diet bundles. Q2 F Y 2 7 · R E ACH Diversified revenue contribution across geographies By Region By City Tier 750 West 51% Tier I 66% South 27% Tier II 8% North 17% Tier III 26% East 6% Region Growth Tier Growth West 16% Tier I 13% 20% South 16% Tier II 14% North 12% Tier III 20% East 13% Revenue contribution of domestic revenue only. Map not to scale; for illustrative purposes only. I N F R AS T R UCT UR E Building a scalable, productive network Laboratory Network Service Network 213 5,119 212 5,026 4,536 175 4,150 3,675 3,134 FY22 FY23 FY24 FY25 FY26 H1FY27 FY22 FY23 FY24 FY25 FY26 H1FY27 Over the last 5 years 52 labs added to the network. Over the last 5 years 1,985 service points added — 490 centres added in FY26 alone. 750 116 241 service points added in Q2FY27 Centre: Lab Ratio, up from 211 in FY25 Q2 F Y 2 7 Consolidated Profit & Loss Statement Profit & Loss Statement Rs. Crs.) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenue from Operations 496.8 429.2 15.8% 947.0 815.3 16.2% Costs 361.9 320.3 698.9 617.2 Reported EBIDTA 134.9 108.9 23.9% 248.2 198.0 25.3% Reported EBIDTA % 27.2% 25.4% 180 bps 26.2% 24.3% 190 bps Depreciation 33.0 32.4 65.5 63.3 Other Income 8.5 0.9 13.6 8.4 EBIT 110.4 77.4 42.6% 196.3 143.2 37.1% Finance Cost 7.9 6.4 16.1 10.9 Profit Before Tax 102.5 71.0 44.4% 180.2 132.3 36.2% Current Tax 27.0 18.1 47.8 34.1 Profit After Tax 75.5 52.9 42.7% 132.4 98.1 34.9% PAT Margin 15.2% 12.3% 290 bps 14.0% 12.0% 200 bps H1 F Y 2 7 Balance Sheet Overview Equity & Liabilities Rs. Crs.) Sep-26 Mar-26 Assets Rs. Crs.) Sep-26 Mar-26 Equity 1653.3 1524.6 Non-current Assets 1704.4 1669.4 Property, Plant and Equipment 222.0 215.3 Equity Share Capital 41.5 41.5 ROU Assets 230.2 194.7 Other Equity 1600.0 1471.7 Goodwill 660.3 660.2 Non-Controlling Interest 11.8 11.4 Other Intangibl [Showing first 8,000 characters — download PDF for full document]